Beijing Luzhu Biotechnology Co., Ltd. (HKG:2480)

Market Cap	3.05B -27.0%
Revenue (ttm)	n/a
Net Income	-155.17M
EPS	-0.78
Shares Out	198.91M
PE Ratio	n/a
Forward PE	26.15
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200
Open	15.33
Previous Close	15.35
Day's Range	15.33 - 15.33
52-Week Range	12.00 - 25.98
Beta	-0.66
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 26, 2026

About HKG:2480

Beijing Luzhu Biotechnology Co., Ltd., a biotechnology company, develops human vaccines and therapeutic biologics to prevent and control infectious diseases, and to treat cancer and autoimmune diseases in Mainland China. The company is developing LZ901, a recombinant herpes zoster vaccine for which a biologics license application (BLA) has been submitted; K3, a recombinant human anti-tumor necrosis factor-alpha monoclonal antibody injection that has completed a Phase 1 clinical trial for the treatment of autoimmune diseases, such as rheumatoid ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 213
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2480

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 11, 2026

Data Sources Report a data error